Navigation Links
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
Date:2/28/2008

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million

investment on top of $75 million previous investment

AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.

"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."

"We are investing in the clear value we see in Arriva's late-stage inhaled protein rAAT, a replacement product for the treatment of hereditary emphysema," said Florian Schonharting, partner of Nordic Biotech. "Our goal with Arriva is to provide financing and through board participation, help the company become a recognized, fully integrated biotech concern," added Christian Hansen, partner of Nordic Biotech.

"MPM has been a supporter of Arriva and the company's mission since 2002," said Ansbert Gadicke, General Partner, MPM Capital. "We continue to believe that there is significant potential in the company's respiratory product pipeline and are involved in this financing because we anticipate that Arriva will successfully capitalize on its IP and other assets."

About Arriva:

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonar
'/>"/>

SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... -- Flexpoint Ford, a private equity firm focused on ... it has entered into a partnership with Alan ... Kastle Therapeutics, LLC (Kastle).  The new company, headquartered in ... developing and commercializing pharmaceuticals targeted toward diseases with high ... already approved for marketing, as well as clinical assets ...
(Date:7/30/2015)... 30, 2015   HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are ... announced total revenue of $73.6 million for the ... million for the quarter ended June 30, 2014. ... million, or nine percentage points, during the three ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
(Date:7/30/2015)... , ... July 30, 2015 , ... ... has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza for ... by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. These ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Google recently announced ... upcoming dedicated web site. As discussed in a June 8, 2015 article published by ... reported so far have been caused by its computer-driven cars, which such industry players ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. ... Palliative Care Administrator. Dr. Demoratz is a strong proponent of early access to ...
(Date:7/30/2015)... ... ... The need for accessibility is never greater than when we find ourselves ... as visiting friends and family during these critical moments, hospitals around the Pennsylvania region ... by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series A ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is ... Dr. Clevens has worked closely with the university, developing a strong presence and a ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... a move much appreciated, the US Consumer Product Safety Commission ... under the name BABYBJ'RN? Feeding Spoons. , The company ... move was taken in response to consumer feedback regarding the ... use, the tips of the spoon were observed to soften ...
... a new technique to rapidly detect and precisely ... treatments usually required. ,The technique, called desorption ... create a new class of fast, accurate detectors ... security, said R. Graham Cooks, the Henry Bohn ...
... as he checked himself into a treatment centre near his ... Elena Fondacaro, his manager: "Verne was in rehab and now ... illness that comes and goes ... and Verne realised he ... he's determined to maintain his sobriety." ,In ...
... going cross-eyed even though his optician has reassured him that he ... taking up wearing sunglasses to have his eyes covered all the ... But I can see it when I look in the mirror ... said I should put then on so that people don't have ...
... pressure may seem like something that only adults get, ... children can develop it too -- and just as ... risks to children's hearts, brains and lives. ... pressure, surgery is the best option for those with ...
... may be another reason for pregnant and nursing women to ... vegetables like broccoli and cabbage// – it could help protect ... life. ,A new study by scientists from ... laboratory mice, found that supplements of a key phytochemical found ...
Cached Medicine News:Health News:New Technique to Identify Bacteria for Food Safety 2Health News:New Technique to Identify Bacteria for Food Safety 3Health News:Surgery, the Best Option for Kids With High Blood Pressure 2Health News:Surgery, the Best Option for Kids With High Blood Pressure 3Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 2Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 3
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits allseven multichannel ... tip cone modules. Both ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
Medicine Products: